Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. - Wikidata - wikimedia - TriplyDB

Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease.

Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease.

http://www.wikidata.org/entity/Q33943891

about

Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffee The promise of neuroprotective agents in Parkinson's disease Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease Neuroprotective and anti-inflammatory properties of a coffee component in the MPTP model of Parkinson's disease Available and emerging treatments for Parkinson's disease: a review Adenosine signaling and function in glial cells Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders.Neuroprotection by caffeine and adenosine A2A receptor blockade of beta-amyloid neurotoxicity The role of early life environmental risk factors in Parkinson disease: what is the evidence?Antioxidant and Antiradical Activity of Coffee Zebrafish: A Model for the Study of Toxicants Affecting Muscle Development and Function Caffeine: cognitive and physical performance enhancer or psychoactive drug?Beneficial and detrimental role of adenosine signaling in diseases and therapy Dietary factors in the etiology of Parkinson's disease.Adenosine receptors as drug targets--what are the challenges?Adenosine A(2A) Receptor Antagonists and Parkinson's Disease Inactivation of the adenosine A2A receptor protects apolipoprotein E-deficient mice from atherosclerosis Identification of zebrafish A2 adenosine receptors and expression in developing embryos A genetic basis for the variable effect of smoking/nicotine on Parkinson's disease.Systemic inflammation regulates microglial responses to tissue damage in vivo The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance.Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease.Effects of adenosine receptor antagonists in MPTP mouse model of Parkinson's disease: mitochondrial DNA integrity.Caffeine and a selective adenosine A2A receptor antagonist induce sensitization and cross-sensitization behavior associated with increased striatal dopamine in mice.Gene-Environment Interaction in Parkinson's Disease: Coffee, ADORA2A, and CYP1A2.Adenosine A2A receptor antagonism reverses inflammation-induced impairment of microglial process extension in a model of Parkinson's disease Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration metabolic profiling of Parkinson's disease and mild cognitive impairment.Role of microglia adenosine A(2A) receptors in retinal and brain neurodegenerative diseases.Genetics of caffeine consumption and responses to caffeine.Astrocytes and therapeutics for Parkinson's disease.Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease.Gut feelings about smoking and coffee in Parkinson's disease.Deletion of adenosine A₁ or A(₂A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease Caffeine increases striatal dopamine D2/D3 receptor availability in the human brain.Association of Coffee Consumption With Total and Cause-Specific Mortality in 3 Large Prospective Cohorts Caffeine alters proliferation of neuronal precursors in the adult hippocampus Modulation of neuroimmunity by adenosine and its receptors: metabolism to mental illness International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update Modulators of nucleoside metabolism in the therapy of brain diseases.

P2860

Q21092426-0976D455-B6F0-4D03-B3B4-3B6140CE14BC Q21129436-64E6BBE2-0310-422B-BD7A-00DD13BFE1E2 Q24604052-5A46D5CE-99E2-4807-9514-8C07B765E56D Q24630237-6358482F-72B2-4C5A-AE4A-F5728820336C Q24633444-42EB9EB7-9779-43EF-8183-0F9E436AA26A Q24634273-AEC2B366-2FBB-4487-862E-DA1A20ACEA62 Q24657796-2FDA663C-AD07-4E8E-A8D8-8317F7CBB274 Q24672753-62E942D8-E551-440E-805A-B6F4C87B0EB9 Q24815642-963E929D-0C26-4119-B025-1B8E16FC5855 Q26866338-15317656-65CF-47CD-B307-047881A8CBCA Q28078475-7C1ED835-FDBD-47CA-8C9D-A6419D8D2B7C Q28080581-1D6F2DE7-79B8-44A4-B960-21E8989393F3 Q28080872-BF6FDF52-FA43-4C3E-A000-409B00E881F5 Q28085390-5CFCC36F-B12C-4356-B496-491AB77C219D Q29346491-7B69F0CF-CD33-444B-AA26-572BDDAADEFD Q29346492-5A7D5760-66F4-494D-A077-06B753D58DFA Q30435620-9241CD83-0130-462B-A272-3F8154A7C130 Q30436906-25A3C223-3BCB-4FC5-9B45-881D8B628DA9 Q30531483-77FAA62F-FAFB-4862-9BBA-B2B15A5E3C7A Q30643015-98EDA1EC-C39E-4728-A72F-D246AF891B65 Q33615756-7B8F883C-5AB3-447A-807F-4B1987A01EAD Q33645872-B535072F-FED6-4A26-BB95-86600ADE9E58 Q33645993-8947CCD7-FDE8-4FD4-97E3-1B3B00B2F2F4 Q33745754-4DC409CD-F06E-4C83-91EF-BC7B9F6FE089 Q33782664-DD50A687-B10C-421F-ACA6-649B68EEBCBA Q33811654-3DE3612C-3C96-4FFE-9EA8-5D0F53527516 Q33828847-8770CD18-1CC8-47D9-B447-AECEC4E95743 Q33835701-B9463CC2-1784-4588-8A78-53B5FE17B919 Q34014053-AB3C748E-8CC5-4AEC-A0F4-5BB256B15A3C Q34119748-2A2963E6-9AB7-4CE3-934C-411D370EF778 Q34168266-01F00DAC-015E-47BF-A5D1-06E4A4157AC3 Q34269340-558F7E90-289F-4259-B414-899001F17436 Q34416404-5CB6975E-F03A-4670-A669-F0FE611078F7 Q34419833-1652F39E-D342-43BD-A04A-F8E1FCF4BDC4 Q34471546-1A2ACBB3-B70B-45E2-928A-DFD423B326AD Q34501906-C9C40245-0A80-45C3-9EFF-E5E581D6102A Q34604570-829902E5-DD5B-488A-AE49-2AE5C140070E Q34615473-2CFD1555-2CCC-44F9-A3DC-F828F7C547E6 Q34701303-8BCBEF99-6533-466D-9519-00613974117E Q34842250-7199594C-AD83-494D-ABAF-61E29D6A6AC8

P2860

Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease.

http://www.wikidata.org/entity/Q33943891

description

2001 nî lūn-bûn

@nan

2001 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Neuroprotection by caffeine an ...... model of Parkinson's disease.

@ast

Neuroprotection by caffeine an ...... model of Parkinson's disease.

@en

type

label

Neuroprotection by caffeine an ...... model of Parkinson's disease.

@ast

Neuroprotection by caffeine an ...... model of Parkinson's disease.

@en

prefLabel

Neuroprotection by caffeine an ...... model of Parkinson's disease.

@ast

Neuroprotection by caffeine an ...... model of Parkinson's disease.

@en

P1433

Q33943891-2EC5010D-6D19-4DD1-B2D3-D9204F0B403B

P1476

Q33943891-C389B0ED-48DC-49AC-AF0B-D6224CE0AE9D

P2093

Q33943891-041D7B90-DFA0-499D-96C1-40002253D877

Q33943891-6F7D79C1-8EB2-477A-A2D5-2BDA8803340F

Q33943891-86A3056D-E494-44E5-9162-7F3B6AA45B1E

Q33943891-98C5D81B-EA2B-4CC0-980C-9C2D6BDD7601

Q33943891-99F89A73-C0AB-437F-A00C-F92710393F2B

Q33943891-9C6BAC27-21EE-4DA0-87A9-659D4ACFBFC1

Q33943891-B2421590-DB2A-42EE-9058-B5BCCE066631

Q33943891-BC2F2069-A30B-4CEA-93AC-03FC4CCD494E

Q33943891-DCC24D2D-A997-4AFB-87B0-B5798FFD8529

Q33943891-FEF663F6-5F87-401E-966C-5A3D4A93A1B5

P304

Q33943891-2ABDF672-6F87-4088-910A-74BBF4AE884A

P31

Q33943891-29F09731-5788-4CA4-AF64-7162290C87A6

P356

Q33943891-9B8503F1-6A50-492D-BE9B-DF0D44C63F0C

P407

Q33943891-5CC0028C-250E-490F-9C10-A18123DCDA8B

P433

Q33943891-9FFF2653-72C0-45C1-8B62-B789DC5AFC71

P478

Q33943891-C4879A25-6815-4CE3-B0B8-5C4C3589E94E

P577

Q33943891-8A4D7BB5-B83B-47FB-8961-5DA4ECBC766B

P698

Q33943891-AB57BBAD-0554-45F0-818D-58EC67426477

P921

Q33943891-8416CDE2-A9D7-40AC-9B1B-CDBCFF234B7D

P932

Q33943891-F75F77C9-16CB-4443-848A-6B12F5E3A2D5

P356

JNEUROSCI.21-10-J0001.2001

P1433

Journal of Neuroscience

P1476

Neuroprotection by caffeine an ...... a model of Parkinson's disease

@en

P2093

J F Chen

http://www.w3.org/2001/XMLSchema#string

J P Petzer

http://www.w3.org/2001/XMLSchema#string

K Castagnoli

http://www.w3.org/2001/XMLSchema#string

K Xu

http://www.w3.org/2001/XMLSchema#string

M A Schwarzschild

http://www.w3.org/2001/XMLSchema#string

M Beilstein

http://www.w3.org/2001/XMLSchema#string

N Castagnoli

http://www.w3.org/2001/XMLSchema#string

P K Sonsalla

http://www.w3.org/2001/XMLSchema#string

R Staal

http://www.w3.org/2001/XMLSchema#string

Y H Xu

http://www.w3.org/2001/XMLSchema#string

P304

RC143

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1523/JNEUROSCI.21-10-J0001.2001

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2001-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11319241

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

6762498

http://www.w3.org/2001/XMLSchema#string